Featured Research Search Results

Looking at Tumor DNA Before Chemotherapy to Predict Cancer Recurrence in People with High-Risk, Early-Stage Breast Cancer

Clinicaltrials.gov identifier:
NCT06401421

Treatment
Biomarker study for people with early-stage breast cancer

Testing a Shorter Course of Chemo- and Immunotherapy for People With Early-Stage Triple-Negative Breast Cancer

Clinicaltrials.gov identifier:
NCT05929768

Treatment
Treatment study for early-stage triple-negative breast cancer

Olaparib with Cediranib or Ceralasertib for People with Advanced or Metastatic Breast Cancer and with a BRCA1 or BRCA2 Mutation

Clinicaltrials.gov identifier:
NCT04090567

Treatment
Treatment study for people with advanced breast cancer who have a BRCA1 or BRCA2 genetic mutation and who were previously treated with a PARP inhibitor

New Treatment in People with Triple Negative Breast Cancer or Advanced Solid Tumors

Clinicaltrials.gov identifier:
NCT06022029

Treatment
Treatment study for people with triple negative breast cancer, advanced solid tumors or lymphomas

ShareForCures®: Susan G. Komen's People-Powered, Data-Driven Breast Cancer Research Registry

Clinicaltrials.gov identifier:
NCT05654246

Surveys, Registries, Interviews
Registry for anyone diagnosed with breast cancer

Study of the PARP inhibitor AZD9574 Alone and Combined with Other Cancer Medicines to Treat People with Advanced Solid Cancers (CERTIS1 Study)

Clinicaltrials.gov identifier:
NCT05417594

Treatment
Treatment study for people with advanced breast, ovarian, pancreatic or prostate cancer or gliomas

WISDOM Study: Women Informed to Screen Depending on Measures of Risk

Clinicaltrials.gov identifier:
NCT02620852

Prevention
Genetic testing and breast cancer screening

Observing People and Families Affected by Li-Fraumeni Syndrome (TP53 Mutation )

Clinicaltrials.gov identifier:
NCT01443468

Surveys, Registries, Interviews
Registry for people with Li-Fraumeni syndrome (LFS) or from LFS families

A Surveillance Program for Women at High Risk for Breast Cancer (CAPSBRACA)

Clinicaltrials.gov identifier:
NCT03729115

Surveys, Registries, Interviews
Screening study for women at risk for breast cancer due to an inherited mutation or other risk factor

TAPUR Study: Testing FDA Approved Drugs Targeting Tumor Biomarkers in People with Advanced Stage Cancer

Clinicaltrials.gov identifier:
NCT02693535

Treatment
Cancer treatment study for people with advanced solid tumors

Self -Perception and Intimacy After the Cancer Experience (SPICE)

Surveys, Registries, Interviews
Online survey for cancer survivors ages 18-39 years old about sexual health

Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib

Clinicaltrials.gov identifier:
NCT04550494

Treatment
Treatment study for people with advanced solid tumors

Helping Latinas Understand Their Risk for Breast Cancer and Get Breast Cancer Care

Clinicaltrials.gov identifier:
NCT05483283

Prevention
Latinas with a high risk of breast cancer

Cancer Experience Registry

Surveys, Registries, Interviews
Online survey for patients and caregivers focusing on multiple aspects of cancer

Treating Metastatic Breast or Pancreatic Cancer in People with an Inherited BRCA or PALB2 Mutation Using Chemotherapy and Patients’ Stem Cells

Clinicaltrials.gov identifier:
NCT04150042

Treatment
Treatment study for metastatic breast or pancreatic cancer in people with an inherited BRCA1 or BRCA2 mutation

Treatment with an ATR Inhibitor for Advanced or Metastatic Solid Tumors

Clinicaltrials.gov identifier:
NCT04657068

Treatment
Advanced solid tumors

Blood Tests to Measure Ovarian Reserves in Women with a BRCA Mutation or Women Treated for Early-Stage Breast Cancer

Clinicaltrials.gov identifier:
NCT00823654

Prevention
Study for premenopausal women with early-stage breast cancer and high-risk women with BRCA mutations and no evidence of breast or ovarian cancer

Talazoparib for People with Metastatic Breast Cancer Who Have Acquired (Somatic) BRCA Mutations

Clinicaltrials.gov identifier:
NCT03990896

Treatment
Treatment study for people with metastatic breast cancer without a known mutation in BRCA1 or BRCA2, who learn they have a BRCA1 or BRCA2 acquired tumor mutation (somatic mutation)